Home > PE Ratio > CONCORD DRUGS

CONCORD DRUGS
PE (Price/Earnings) Ratio

The Current P/E Ratio of CONCORD DRUGS is 48.83.

Share Price ₹75.8Sep 24,2026
Market Cap ₹100.1 Cr
Earnings-TTM₹2.1 CrTTM-Consolidated Results
Price/Earnings48.83xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for CONCORD DRUGS
Please provide your vote to see the results
CONCORD DRUGS is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of CONCORD DRUGS

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of CONCORD DRUGS is calculated as :

Current Market Cap [ ₹100.1 Cr] as on Sep 24,2026

(/) Earnings [ ₹2.1 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 48.83x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for CONCORD DRUGS , the investors are currently willing to pay 48.83 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CONCORD DRUGS !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of CONCORD DRUGS over the last five years.

Historical PE (Price/Earnings) ratio chart of CONCORD DRUGS


PE Ratio Performance Analysis for CONCORD DRUGS

- CONCORD DRUGS 's latest p/e ratio is 48.83x.

- CONCORD DRUGS 's p/e ratio for fiscal years ending Mar2025 to Mar2022 averaged 52.19x.

- CONCORD DRUGS 's operated at median p/e ratio of 74.45x from fiscal years ending March 2018 to 2022.

- Looking back at the last 4 fiscal years, CONCORD DRUGS 's p/e ratio peaked in Mar2025 at 92.44x.

- CONCORD DRUGS 's p/e ratio hit its five-year low in Mar2022 of 15.9x.


How does CONCORD DRUGS 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
CONCORD DRUGS 2.0548.83100.1
SUN PHARMACEUTICAL INDUSTRIES LTD12,172.7036.52444,597.0
DIVIS LABORATORIES LTD2,925.0087.25255,195.0
TORRENT PHARMACEUTICALS LTD2,156.0087.06187,712.0
CIPLA LTD3,364.8433.71113,423.0
DR REDDYS LABORATORIES LTD3,169.3031.61100,195.0
MANKIND PHARMA LTD2,055.1149.74102,229.0
LUPIN LTD5,551.0117.2895,939.4
ZYDUS LIFESCIENCES LTD4,492.2026.20117,705.0
AUROBINDO PHARMA LTD3,712.7426.6698,965.0
LAURUS LABS LTD1,090.76100.37109,481.0

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CONCORD DRUGS 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 17.28x
Max industry PE 100.37x
Median industry PE 36.52x
Average industry PE 49.57x



You may also like the below Video Courses